We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®

News   Mar 19, 2015

 
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
 
 
Advertisement
 

RELATED ARTICLES

SARS-CoV-2 Variants Can Evade Antibodies That Neutralize Original Virus

News

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic.

READ MORE

Chronic Skin Inflammation Molecular Mechanisms Identified

News

Researchers have identified new molecular mechanisms as causes for chronic skin inflammation like in atopic dermatitis (AD or neurodermatitis) and psoriasis that could provide suitable starting points for new therapies.

READ MORE

NIH Closes Enrolment for Two Sub-Studies in ACTIV-3 Trial

News

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrolment in two sub-studies. The first sub-study was examining the investigational monoclonal antibody therapy VIR-7831 and the second was evaluating a combined monoclonal antibody therapy containing BRII-196 and BRII-198.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE